Editas
The FDA approved three new gene therapy products in 2024 and expanded indications for two others, all for rare diseases.
Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel
Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on investigational candidates.
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
Editas Medicine Raises $57M by Selling Future Payments From CRISPR Licensing Deal With Vertex Pharma
Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and payments it is owed under an earlier deal with Vertex.
Jul 24, 2024